Dstr mal les s/n/h/f/g 0.6-1
CPT 17271 covers the destruction of a cancerous or pre-cancerous skin lesion measuring between 0.6 and 1.0 centimeters on the scalp, neck, hands, feet, or genitals. This typically involves freezing, burning, or laser treatment to remove abnormal tissue.
This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.
RVU breakdown
Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High
NCCI bundling edits
Loading bundling edits…
Billing tips
Measure lesions precisely and document the greatest diameter in centimeters (not millimeters) in the operative note; 17271 covers 0.6-1.0 cm specifically
Impact: Incorrect sizing can result in downcoding to 17270 ($133.81) or upcoding denial to 17272, representing a $28-60 payment difference per lesion
Bill non-facility (office) setting when appropriate to capture the full $162.06 rate rather than facility rate of $103.19
Impact: Setting-of-service optimization yields $58.87 additional revenue per procedure (36% increase)
Document anatomical location explicitly as scalp, neck, hands, feet, or genitalia; generic 'skin' documentation may trigger denial or downcoding to 17000-series codes
Impact: Location-specific codes (17271) reimburse significantly higher than non-specific destruction codes; failure to document can result in $80-100 reduction per lesion
When destroying multiple lesions, list 17271 for the first lesion and use appropriate add-on codes (17272-17276) for additional lesions in the same size range
Impact: Proper sequencing prevents duplicate denials and maximizes reimbursement; first lesion at $162.06, subsequent lesions typically 50-75% of base rate
Obtain pathology confirmation of malignancy before destruction when possible; link appropriate ICD-10 malignancy code (C44.x series) for medical necessity
Impact: Pre-procedure biopsy confirmation reduces denial rate from approximately 15-20% to under 5%; supports medical necessity on audit
Separate visits for biopsy and destruction to avoid bundling; allow pathology results to return before scheduling destruction procedure
Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.
Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.
Help build the field knowledge
MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.